ICMR Licenses Three Indigenous Biomedical Technologies to Emcure and Biological E for Cancer and Infectious Disease Control
核心洞察
The Indian Council of Medical Research (ICMR) has licensed three indigenous biomedical technologies to Emcure Pharmaceuticals and Biological E under its Medical Innovations Patent Mitra initiative.
SHetA2, a first-in-class anti-HPV (搜索) therapeutic candidate for Cervical Intraepithelial Neoplasia (搜索) (CIN), was licensed to Emcure Pharmaceuticals for further development and commercialization.
Two next-generation vaccine technologies targeting Salmonella typhi, Salmonella paratyphi (搜索), and Shigella (搜索) infections were licensed to Biological E Ltd. (搜索), developed at ICMR-NIRBI, Kolkata.
The Indian Council of Medical Research (ICMR) has announced the licensing of three indigenous biomedical technologies to leading Indian pharmaceutical and vaccine manufacturers, marking a significant advancement in the translation of publicly funded research into tangible healthcare products. Facilitated under ICMR's Medical Innovations Patent Mitra initiative, the agreements involve Emcure Pharmaceuticals Ltd. and Biological E Ltd. (搜索), targeting cervical precancerous lesions and enteric bacterial infections, respectively.
The technology transfer encompasses SHetA2, a first-in-class targeted therapeutic candidate for the treatment of Cervical Intraepithelial Neoplasia (搜索) (CIN), and two next-generation vaccine technologies against major enteric bacterial pathogens.
SHetA2: A First-in-Class Anti-HPV (搜索) Therapeutic
SHetA2 represents a novel approach to addressing human papillomavirus (HPV (搜索))-induced precancerous and cancerous cervical lesions. Developed through an international collaboration between Dr. Showket Hussain at the ICMR National Institute of Cancer Prevention and Research (ICMR-NICPR) and Dr. Doris M. Benbrook at the Stephenson Cancer Center, University of Oklahoma, USA, SHetA2 is designed to selectively eliminate HPV-induced precancerous and cervical cancer (搜索) cells while sparing healthy cells.
The therapeutic candidate has been licensed to Emcure Pharmaceuticals Ltd. for further development, manufacturing, and commercialization. According to ICMR, the technology has the potential to provide a safe, affordable, and minimally invasive treatment option for cervical cancer (搜索), addressing a significant unmet need in women's health.
Next-Generation Enteric Vaccines Licensed to Biological E
The second component of the technology transfer involves two vaccine technologies developed by Dr. Santasabuj Das and his research team at the ICMR–National Institute of Research in Bacterial Infections (ICMR-NIRBI) in Kolkata. These have been licensed to Biological E Ltd. (搜索):
- A fusion construct containing Salmonella typhi outer membrane protein, positioned as a promising next-generation typhoid vaccine candidate.
- A recombinant vaccine composition targeting Salmonella typhi, Salmonella paratyphi, and Shigella infections, designed to provide broader protection against major enteric bacterial pathogens.
Together, these vaccine technologies aim to strengthen India's capacity to combat enteric bacterial diseases through indigenous innovation.
Strengthening India's Biomedical Innovation Ecosystem
Dr. Rajiv Bahl, Secretary of the Department of Health Research (DHR) and Director General of ICMR, emphasized the strategic importance of these licensing agreements. "ICMR is committed to ensuring that publicly funded research translates into products that improve health outcomes. Through initiatives such as Medical Innovations Patent Mitra, we are strengthening the pathway from scientific discovery to commercialization by fostering partnerships between researchers and industry," Dr. Bahl stated. "These technology transfers demonstrate the growing maturity of India's biomedical innovation ecosystem and represent another step towards achieving self-reliance in healthcare innovation."
As India's apex biomedical research organization, ICMR has built an integrated innovation ecosystem that supports healthcare technologies across the entire innovation continuum—from discovery and intellectual property protection to clinical validation, regulatory facilitation, and commercialization. The Medical Innovations Patent Mitra initiative provides innovators with structured support for patent filing, technology transfer, and licensing, while the complementary MedTech Mitra program facilitates regulatory guidance, clinical evaluation, and market access for indigenous medical technologies.
The licensing of these three technologies reflects the growing convergence of scientific excellence, strategic international collaborations, and industry partnerships in India's biomedical sector, with the shared goal of delivering affordable, high-quality healthcare solutions both domestically and globally.